Literature DB >> 20091423

Growth kinetic analysis of bi-recombinant poliovirus vaccine strains.

Vaia Pliaka1, Evaggelos Dedepsidis, Zaharoula Kyriakopoulou, Georgia Papadi, Dimitris Tsakogiannis, Anastassia Pratti, Stamatina Levidiotou-Stefanou, Panayotis Markoulatos.   

Abstract

Attenuated strains of Sabin poliovirus vaccine replicate in the human gut and in rare cases may cause vaccine-associated paralytic poliomyelitis (VAPP). Mutations at specific sites of the genome and recombination between Sabin strains may result in the loss of the attenuated phenotype of OPV (Oral Poliovirus Vaccine) strains and the acquisition of traits characteristic of wild polioviruses, such as increased neurovirulence and loss of temperature sensitivity. In this study, we determined the phenotypic traits such as temperature sensitivity and growth kinetics of eight OPV isolates (six bi-recombinant and two non-recombinant). The growth phenotype of each isolate as well as of Sabin vaccine strains in Hep2 cell line at two different temperatures (37 and 40 degrees C) was evaluated using two different assays, RCT test (Reproductive Capacity at different Temperatures) and one-step growth curve analysis. Moreover, the nucleotide and amino acid positions in the genomes of the isolates that have been identified as being involved in the attenuated and thermo sensitive phenotype of Sabin vaccine strains were investigated. Mutations that result in loss of the attenuated and thermo sensitive phenotype of Sabin vaccine strains were identified in the genomes of all isolates. Both mutations and recombination events correlated well with the reverted phenotypic traits of OPV-derivatives. In the post-eradication era of wild polioviruses, the identification and the characterization (genomic and phenotypic) of vaccine-derived polioviruses become increasingly important in order to prevent cases or even outbreaks of paralytic poliomyelitis caused by neurovirulent strains.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20091423     DOI: 10.1007/s11262-010-0448-9

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  60 in total

1.  The natural genomic variability of poliovirus analyzed by a restriction fragment length polymorphism assay.

Authors:  J Balanant; S Guillot; A Candrea; F Delpeyroux; R Crainic
Journal:  Virology       Date:  1991-10       Impact factor: 3.616

2.  Recombinant Sabin environmental isolates in Greece and Cyprus.

Authors:  E Paximadi; I Karakasiliotis; D Papaventsis; G Papageorgiou; P Markoulatos
Journal:  J Appl Microbiol       Date:  2007-11-21       Impact factor: 3.772

3.  Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y.

Authors:  N La Monica; V R Racaniello
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  Improved genotyping vaccine and wild-type poliovirus strains by restriction fragment length polymorphism analysis: clinical diagnostic implications.

Authors:  A Georgopoulou; P Markoulatos; N Spyrou; N C Vamvakopoulos
Journal:  J Clin Microbiol       Date:  2000-12       Impact factor: 5.948

5.  Mutation of a single conserved nucleotide between the cloverleaf and internal ribosome entry site attenuates poliovirus neurovirulence.

Authors:  Nidia De Jesus; David Franco; Aniko Paul; Eckard Wimmer; Jeronimo Cello
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

6.  Genomic analysis of recombinant sabin clinical isolates.

Authors:  Eleni Paximadi; Ioannis Karakasiliotis; Zissis Mamuris; Constantinos Stathopoulos; Vassilis Krikelis; Panayotis Markoulatos
Journal:  Virus Genes       Date:  2006-04       Impact factor: 2.332

7.  High diversity of poliovirus strains isolated from the central nervous system from patients with vaccine-associated paralytic poliomyelitis.

Authors:  M M Georgescu; F Delpeyroux; M Tardy-Panit; J Balanant; M Combiescu; A A Combiescu; S Guillot; R Crainic
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

8.  Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Authors:  A Martin; D Benichou; T Couderc; J M Hogle; C Wychowski; S Van der Werf; M Girard
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

9.  Paralytic poliomyelitis in Romania, 1984-1992. Evidence for a high risk of vaccine-associated disease and reintroduction of wild-virus infection.

Authors:  P M Strebel; A Aubert-Combiescu; N Ion-Nedelcu; S Biberi-Moroeanu; M Combiescu; R W Sutter; O M Kew; M A Pallansch; P A Patriarca; S L Cochi
Journal:  Am J Epidemiol       Date:  1994-12-15       Impact factor: 4.897

10.  Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3.

Authors:  Stephen Guest; Evgeny Pilipenko; Kamal Sharma; Konstantin Chumakov; Raymond P Roos
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more
  4 in total

1.  Viral kinetics of enterovirus 71 in human abdomyosarcoma cells.

Authors:  Jing Lu; Ya-Qing He; Li-Na Yi; Hong Zan; Hsiang-Fu Kung; Ming-Liang He
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

2.  Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.

Authors:  V Pliaka; Z Kyriakopoulou; D Tsakogiannis; I G A Ruether; C Gartzonika; S Levidiotou-Stefanou; A Krikelis; P Markoulatos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-05       Impact factor: 3.267

3.  Molecular and Phenotypic Characterization of a Highly Evolved Type 2 Vaccine-Derived Poliovirus Isolated from Seawater in Brazil, 2014.

Authors:  Klécia Marília S de Melo Cassemiro; Fernanda M Burlandy; Mikaela R F Barbosa; Qi Chen; Jaume Jorba; Elayse M Hachich; Maria I Z Sato; Cara C Burns; Edson E da Silva
Journal:  PLoS One       Date:  2016-03-28       Impact factor: 3.240

4.  Whole genomic sequence and replication kinetics of a new enterovirus C96 isolated from Guangdong, China with a different cell tropism.

Authors:  Jing Lu; Huanying Zheng; Yong Zhang; Xue Guo; De Wu; Hui Li; Leng Liu; Hanri Zeng; Lina Yi; Ling Fang; Yanling Mo; Wenbo Xu; Changwen Ke
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.